Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III crossover trial of YW17 versus Aldurazyme in mucopolysaccharidosis type I
IRCT20150303021315N30Phase 3Completed
- Sponsor
- CinnaGen
- Start
- May 2022
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of laronidase, acetaminophen and diphenhydramine in mucopolysaccharidosis type I, sponsored by CinnaGen. Primary endpoints: Mean urinary glycosaminoglycan adjusted by urinary creatinine, 6-minute walk test distance and 3 more. Started May 2022; status: completed.
02
Drugs
laronidaseacetaminophendiphenhydramine
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on IRCT20150303021315N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N30.